Raymond James Financial
RVPH

Raymond James Financial’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Raymond James Financial’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-700
Closed -$3.91K – 5429
2025
Q4 		$3.91K Sell
700
-50
-7% -$556 ﹤0.01% 5152
2025
Q3 		$5.53K Hold
750
– – ﹤0.01% 4945
2025
Q2 		$5.72K Sell
750
-7
-0.9% -$109 ﹤0.01% 6132
2025
Q1 		$14.4K Buy
757
+57
+8% +$1.79K ﹤0.01% 4750
2024
Q4 		$25.3K Buy
+700
New +$19.5K ﹤0.01% 4699

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Raymond James Financial's RVPH Position: Q1 2026 in Review

Raymond James Financial sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2026, closing a stake of 700 shares — an estimated $3.91K sold.

Raymond James Financial first reported a position in RVPH in Q4 2024 and held it in 5 quarters. The position peaked at $25.3K in Q4 2024. 35 funds tracked by Wall St. Rank hold RVPH as of Q1 2026.

  • Raymond James Financial reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 700 REVIVA PHARMA HLDGS INC shares in Q1 2026, an estimated $3.91K.
  • Raymond James Financial first reported a position in REVIVA PHARMA HLDGS INC in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's REVIVA PHARMA HLDGS INC position peaked at $25.3K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.